Neoplasma Vol.55, No.2, p.107-112, 2008
|
| Title: Autologous stem cell transplantation in first-line treatment of high-risk
aggressive non-Hodgkin’s lymphoma |
| Author: A. VRANOVSKY, M. LADICKA, J. LAKOTA |
|
Abstract: A single center, retrospective analysis evaluating the outcome of patients with poor-risk aggressive non-Hodgkin’s lymphoma (NHL) treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT) as a part of firstline therapy. Forty-seven patients younger than 65 years with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL) or alk-negative anaplastic large cell lymphoma (ALCL) underwent ASCT between July 1997 and November 2005. Patients with DLBCL and alk-negative ALCL had 2 or 3 age-adjusted International Prognostic Index risk factors. All patients were transplanted after MACOP-B induction therapy followed by 2 courses of DHAP and myeloablative chemotherapy BEM or CBV. The complete response rate to the high-dose therapy was 79% with an estimated 5-year progression-free survival of 66%. At a median follow-up of 35 months (range, 16 to 112 months) the estimated overall survival at five years was 59%. There were 4 treatment-related deaths. Twenty-nine of 47 patients remain in complete remission. Our results confirm the efficacy of high-dose therapy with ASCT during first-line treatment of patients with poor-prognosis aggressive lymphoma, with substantial number of patients cured by using this treatment approach.
|
|
| Keywords: high-dose chemotherapy; autologous transplantation, aggressive non-Hodgkin’s lymphoma |
| Year: 2008, Volume: 55, Issue: 2 |
Page From: 107, Page To: 112 |
|
|
|
|
|
 download file |
|
|
|
|
